Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

M. Cerna



Author of

  • +

    P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P1.01-069 - Reasons for Discontinuation of Treatment with Bevacizumab in Patients with Non-Progressing NSCLC - Retrospective Study (ID 3243)

      09:30 - 09:30  |  Author(s): M. Cerna

      • Abstract
      • Slides

      Background:
      In general, bevacizumab is well-tolerated treatment in patients with advanced, metastatic non-squamous NSCLC. Despite this, permanent discontinuations of bevacizumab occur also before progressive disease (PD), both in clinical trials and in clinical practice. Purpose of this study was to find out the reasons for permanent discontinuation of bevacizumab before PD in patients treated in two centers in the Slovak republic.

      Methods:
      In this retrospective study, approved by the Ethics Committee of the Specialized Hospital of St Zoerardus Zobor, the institutional databases were searched for patients with advanced NSCLC treated with bevacizumab between 2007 and 2013.

      Results:
      Altogether 161 patients were included into the analysis. Patients' characteristics: M/W: 99/62, age: median 61 years (32 - 83), histologically /cytologically confirmed NSCLC: adenocarcinoma/large cell/adenosquamous: 158/2/1. Number of cycles with bevacizumab (induction and maintenance): median 8 (1 - 52), PFS: median 7 months (1 - 42). Bevacizumab was permanently discontinued before PD in 28 of 161 patients (17,4%), in 18 of 161 (11,2%) due to undesirable effects - Table 1. Table 1: Reasons for permanent discontinuation of bevacizumab in non-progressing NSCLC

      Undesirable effects N Other reasons N
      Cavitation 3 Lost to FU 2
      Pneumothoraces 3 Molecular testing, start of TKI 2
      Cerebrovascular event 2 Patients' preference 2
      Gastrointestinal perforation 2 Car accident, death 1
      Hypertensive crisis 2 Planned surgery 1
      Pneumonia 2 Traumatic fractures 1
      Proteinuria 2 Other 1
      Thrombotic event 2
      All 18 All 10


      Conclusion:
      Permanent discontinuation of bevacizumab in non-progressing NSCLC was seen in this study in the similar rate as in the larger trials (Wozniak AJ et al. Clin Oncol [Coll Radiol]. 2015, 27:187-96.) However, some differences are in the type of undesirable effects, which are in part also chemotherapy related.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P2.01-025 - Crizotinib in Advanced ALK-Positive NSCLC - A Retrospective Multicenter Study in the Slovak Republic (ID 3014)

      09:30 - 09:30  |  Author(s): M. Cerna

      • Abstract
      • Slides

      Background:
      Crizotinib has been available in Slovakia since October 2012 for the treatment of adults with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC), based on the therapeutic indication approved by the European Medicines Agency. Purpose of this study was to assess the results achieved with crizotinib in the treatment of advanced NSCLC in clinical practice in Slovakia.

      Methods:
      In this multicenter retrospective study, approved by the Ethical Committee of the Specialized Hospital of St Zoerardus Zobor, the data of 30 ALK-positive patients were reviewed. FISH with break-apart probes was used for the confirmation of ALK rearrangement in all cases. MedCalc[®] was used for the statistical analyses.

      Results:
      Between October 2012 and August 2014, 20 out of 30 ALK-positive patients were treated with crizotinib. Ten patients did not receive crizotinib: five due to on-going first-line chemotherapy, five due to other reasons. Characteristics of the treated patients: M/W: 6/14, age (years) median 56, range 23-77, PS (ECOG/WHO): 0/1/2/3: 1/10/4/5, Histology: 19 patients adenocarcinoma, 1 NSCLC, NOS. Treatment results: RR was evaluated in 20 patients: PR + CR: 13 (12+1), 65% (95% CI: 41-85), SD: 3, 15% (95% CI: 3-38), PD: 3, 15% (95% CI: 3-38), NS: 1, 5%, DCR: 16, 80% (95% CI: 56-94), PFS: Kaplan-Meier estimate: 13 months (95% CI: 7 -18), 0S (with 60% of patients censored): 19 months (95%CI: 12 - NR), PS: significant improvement within 2 months (mean dif. –0.95, P=0.0021), toxicities grade 3/4 occurred in 11 of 20 patients (55%), hematologic: 0, non-hematologic: hepatotoxicity 3/1, pneumonitis: 1/0, diarrhea 1/0, nausea: 3/0, vomiting: 1/1, vision disorder: 1/0, peripheral edema: 1/0, QT-interval prolongation: 1/0. Crizotinib was permanently discontinued due to toxicity in only two patients.

      Conclusion:
      Treatment results seen in this retrospective study are encouraging and consistent with the published data from the prospective trials.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.